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Abstract: The epidermal growth factor receptor (EGFR) pathway has emerged as an important target in the treatment of 
non-small cell lung cancer (NSCLC). Currently available EGFR inhibitors approved for the therapy of NSCLC include 
the small molecules erlotinib and gefitinib. They are administered orally and interfere with the intracellular tyrosine 
kinase domain. These agents appear most effective in patients with tumors which are highly dependent on the EGFR 
signaling pathway because of EGFR activating mutations or amplifications. The use of EGFR tyrosine kinase inhibitors 
prolongs survival in metastatic NSCLC. However, despite the dramatic initial responses to treatment in some cases, 
NSCLC eventually becomes resistant to EGFR-tyrosine kinase inhibitors (TKIs). Mechanisms of resistance include EGFR 
secondary mutations that interfere with drug binding. Besides, molecular cross-talk and redundancy between EGFR and 
other signaling pathways creates alternative pathways for tumor cell proliferation promoting resistance to EGFR 
inhibition such as the amplification of the receptor tyrosine kinases MET. Polymorphisms in EGFR and EGFR pathway-
related genes, as well as in genes involved in drug metabolism and intake/efflux might also predict clinical outcome and 
toxicity. 
Therefore, understanding the mechanisms involved in the EGFR signalling and resistance to EGFR inhibition will provide 
new insights for the development of more effective targeted treatments against NSCLC. 
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INTRODUCTION 
 The activity of anti-cancer drugs can be affected by 
different reasons. As a general rule, individual variation in 
drug effects might stem from variability in the 
pharmacokinetics and/or pharmacodynamics of the 
therapeutic compound and may have both genetic and non 
genetic causes. Most drugs are given systemically and 
therefore are subject to changes in absorbtion, metabolism 
and delivery to the targeted tissues. Tumors can be located in 
body parts into which drugs can not easily penetrate or might 
have increased expression of proteins involved in drug 
efflux/metabolism. Modification in drug targets might also 
affect their effects. 
 One of the most common treatments for cancer is the use 
of cytotoxic drugs. This strategy is based on the differences 
in cell division rates between normal cells and cancer cells. 
However, this treatment includes many side effects. There 
are three major mechanisms of drug resistance in cancer 
cells. First, the uptake of water-soluble drugs which requires 
transporters to enter the cancer cells can be decreased. 
Second, resistance may occur due to the specific properties 
or genetic background of the cancer cell itself or the genetic 
or epigenetic changes that occur after the toxic 
chemotherapy. In particular, cancers are characterized by 
several alterations which might affect the ability of cytotoxic 
drugs to kill the cancer cells such as the changes in cell  
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cycle, reduced apoptosis, increased repair of DNA damage 
and altered metabolism [1]. Third, cancer cell might have 
increased energy-dependent efflux of hydrophobic drugs that 
can easily enter the cells by diffusion through the plasma 
membrane. 
 Therefore, to reduce both the side effects of the cytotoxic 
drugs and the above-mentioned mechanism of drug 
resistance, new molecular therapies are being developed 
which attack the specific signalling pathways that play an 
important role in the development, growth and progression 
of the tumors. These new drugs are targeted to specific 
molecular targets or genes involved in cancer development 
(“targeted therapy”) and should not only reduce the side-
effects but also result in higher efficacy and activity against 
tumors. 
 One of the most important mechanisms in signalling 
pathways in cells is the phosphorylation of proteins that is 
carried out by protein kinases. Protein kinases are involved 
in the regulation of cell proliferation, migration, 
differentiation, metabolism and apoptosis. Two important 
protein kinases are the tyrosine kinases and serine/threonine 
kinases. Tyrosine kinases catalyze the phosphorylation of 
tyrosine amino acid residues whereas serine/threonine 
kinases catalyze the phosphorylation of serine/threonine 
amino acid residues in proteins. Tyrosine kinases are highly 
regulated in the cell as they have important regulatory effects 
in cell homeostasis and signalling pathways. There are two 
classes of tyrosine kinases: receptor tyrosine kinases and 
cellular tyrosine kinases. Receptor tyrosine kinases have an 
intracellular catalytic tyrosine kinase domain, a hydrophobic 
transmembrane domain and an extracellular ligand binding 
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domain [2]. Dimerization of the two receptor tyrosine 
kinases occurs when the ligand binds to the receptors. This 
results in the phosphorylation of the tyrosine residues of the 
intracellular catalytic domains which leads to an active 
conformation and results in the activation of signalling 
pathway within the cell (Fig. 1). 
 The regulation of tyrosine kinases is essential for the 
control of cell growth and cancer may stem from the 
unregulated cell proliferation. This can be caused by 
abnormally constitutively active tyrosine kinases which are 
independent of ligand binding, because of mutations or over-
expression. Therefore, tyrosine kinase inhibitors (TKIs) can 
be used as anti-cancer agents targeting the specific 
unregulated tyrosine kinase activities. TKIs can stabilize 
tumor development, growth and progression in many tumour 
types, have less side-effects when compared to cytotoxic 
drugs and interact synergistically with chemotherapy and 
radiotherapy. 
 The Epidermal Growth Factor Receptor (EGFR) pathway 
is part of a complex signal-transduction network central to 
critical processes in cell proliferation. EGFR is 
overexpressed in 40-80% of NSCLC and plays a crucial role 
in cellular proliferation, differentiation, apoptosis and 
survival [3]. EGFR phosphorylation activates several 
downstream signaling pathways, including the mitogen-
activated protein kinase (MAPK/Erk), phosphotidylinositol-
3 kinase/Akt and the signal transducer and activator of 
transcription (STAT) proteins. These modulate gene 
transcription and protein translation, thereby stimulating 
tumour-cell proliferation, migration, invasion, angiogenesis 
and inhibition of apoptosis. EGFR expression is common in 
a number of epithelial tissues and in various solid tumour 
types, where high levels of EGFR expression correlate with 
more aggressive disease, poorer prognosis and reduced 
chemosensitivity. 
 Against this background, EGFR was identified as an 
attractive target for the development of anticancer drugs, and 
the treatment of non-small cell lung cancer (NSCLC) has 
been improved by the development of the EGFR-TKIs. 
TYROSINE KINASE INHIBITORS 
 Tyrosine kinase receptors have an important role in the 
development and progression in most of the cancer types. 
Most TKIs are designed to target the EGFR, VEGFR and 
PDGFR tyrosine kinase families. The EGFR family includes 
the tyrosine kinase receptors EGFR (ErbB1, Her1), ErbB2 
(Her2), ErbB3 (Her3) and ErbB4 (Her4). When these kinase 
receptors get abnormally activated, cell growth is 
deregulated due to decreased apoptosis and angiogenesis in 
epithelial malignancies. Therefore several TKIs have been 
developed for inhibiting the abnormal signalling in the cell 
which are required for cell growth and division. TKIs which 
target EGFR tyrosine kinases and are used in NSCLC are 
listed in Table 1. 
 Gefitinib and erlotinib have been approved by FDA for 
the treatment of patients with locally advanced or metastatic 
NSCLC after failure of at least one prior chemotherapy 
regimen [4] (Table 1). Furthermore, gefitinib has been 
recently registered in Europe for the first-line treatment of 
patients with EGFR activating mutations. Similarly, gefitinib 
is already an established therapy for pre-treated NSCLC in 
the Asia-Pacific region, where consultations with regulatory 
authorities are ongoing to discuss its potential use in first-
line therapy. 
 They are orally bioavailable and they selectively and 
reversibly bind to the ATP-binding site of the EGFR 
intracellular tyrosine kinase domain. They have a common 
chemical backbone structure and show similar disposition 
characteristics in humans after administration [5] with a 
similar bioavailability, of approximately 60% [6]. 
SELECTIVITY AND EFFICACY 
 Protein tyrosine kinases have a tyrosine kinase domain 
which consists of a C-terminal and an N-terminal lobe. The 
binding site for the downstream proteins is the C-terminal 
 
Fig. (1). General view of the ligand-induced dimerization and activation process of EGFR. 
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lobe. Tyrosine kinase inhibitor selectivity is mostly obtained 
by targeting the highly conserved ATP binding site of the 
tyrosine kinases which is in the cleft between the two lobes 
[7]. In order to obtain the maximum selectivity, tyrosine 
kinase inhibitors are designed to specifically attack the ATP 
binding site of the tyrosine kinases. Selectivity is also 
obtained by using the proximal regions of the ATP binding 
site. The adenine region is used by the inhibitors to increase 
their potency and the sugar region is used for selectivity in 
EGFR inhibitors as they have different amino acids when 
compared to the other receptors [8]. Selectivity pocket and 
channel are not used by ATP-binding and play an important 
role in increasing the inhibitor selectivity and binding 
affinity, while the phosphate binding region can also be used 
to improve selectivity [9]. Hubbard et al. suggested that 
juxtamembrane regions can also be a good target to obtain 
specificity and increase affinity [10]. This region is located 
between the transmembrane segment and kinase domain and 
it autoinhibits the catalytic activity of the receptor tyrosine 
kinases. This region can be targeted for the drugs as the 
sequences are not similar in different juxtamembrane 
segments in different receptor tyrosine kinase families. 
 The selectivity of a tyrosine kinase inhibitor is very 
important in the sense of focusing on tumor cells instead of 
normal cells to minimize the side effects. Furthermore, the 
tyrosine kinase inhibitors, gefitinib and erlotinib, are more 
effective in tumor cells harbouring specific mutations, such 
as the deletion mutations in exon 19 or different point 
mutations (including the most common, L858R) in EGFR-
TK domain [11]. Similarly an inhibitor which is used for 
attacking the overexpression, such as MET inhibitor for 
MET overexpression, may result in inhibition of MET in 
tumor cells, but also in some normal cells with high 
expression of MET. Therefore, selectivity is very important 
for attacking only the desired tumor cells instead of normal 
cells, minimizing the side effects. 
 Selectivity and specifity are increased when an inhibitor 
is able to bind to different conformational states of the 
enzyme. Erlotinib can be an example for this as it can 
recognize and bind to different conformations of EGFR with 
high affinity. This ability seems to be more important than 
the sequence differences of the kinase domain or interaction 
differences with binding site residues [12]. Thus, the crystal 
structure of tyrosine kinases is very important in designing 
tyrosine kinase inhibitors with higher specificity and 
selectivity. As a summary, to increase the selectivity and to 
minimize the side-effects, it is important to design tyrosine 
kinase inhibitors which specifically block certain tyrosine 
kinase or kinases that are found in the abnormal signalling. 
For increasing the selectivity of tyrosine kinase inhibitors 
different mutational status, different sequences and 
conformation states of kinases are also being investigated. 
 In general, different tumor types express different 
number and types of tyrosine kinases while the same type of 
tumors have similar receptor tyrosine kinases both in 
expression and numbers. Administration of tyrosine kinase 
inhibitors that specifically target one of these kinases can be 
effective in tumor types depending on mutations in specific 
oncogenes for their development, such as BCR-ABL in 
leukaemia, specifically targeted by imatinib, according to the 
“oncogene addiction” theory [13]. However, most human 
cancers display multiple genetic abnormalities, which might 
differ also between subsets of the same type of cancer. 
Therefore, a tyrosine kinase inhibitor which inhibits many 
kinases will be more effective in cancer types which occur 
due to overexpression of several kinases. However, although 
this administration seems to be more advantageous as 
multikinase inhibitor can inhibit several types of receptors 
that are overexpressed, there is a still a high variability in the 
number and the types of kinases which might differ also 
between subsets of the same type of cancer, also in NSCLC. 
 Furthermore, EGFR mutations and more importantly 
overexpression of EGFR have a crucial role in the formation 
of NSCLC, but also in the metastic behaviour. Therefore, the 
variability in EGFR overexpression in NSCLC can reduce 
the efficacy of the tyrosine kinase inhibitors. Besides, some 
tyrosine kinase inhibitors might also increase the risk of 
metastasis whereas some tyrosine kinase receptors reduce 
this risk. Since EGFR family plays a very important role in 
metastasis, it is very important to inhibit the specific receptor 
tyrosine kinases that increase the risk of metastasis, while 
not affecting the suppressive receptor tyrosine kinases. 
 Finally, some receptor tyrosine kinases might be tumor 
suppressor genes and the role of one tyrosine kinase receptor 
in one type of cancer can be different in another cancer type. 
Consequently, although mostly receptor tyrosine kinases 
play a role in the formation of tumors, they might also have a 
tumor suppressive properties in different types of cancer. 
Therefore, there is a possibility of a tyrosine kinase inhibitor 
to promote tumor growth such as the tyrosine kinase 
inhibitor canertinib which can stimulate tumor growth as it 
non-selectively targets the EGFR family members. This 
implies that inhibiting a tyrosine kinase can have different 
effects in different cancer types, and this should be carefully 
investigated. 
Table 1. Tyrosine Kinase ?nhibitors (TKIs) of the EGFR Tyrosine Kinase Family Used in the Treatment of NSCLC 
 
Inhibitor Tyrosine Kinase Target Cancer Target Clinical Status 
Gefitinib (Iressa, ZD1839) EGFR Lung, Breast Approved 
Erlotinib (Tarceva, OS1774) EGFR Lung Approved 
Lapatinib (Tykerb, GW572016) ErbB1, ErbB2 NSCLC, breast, gastric Approved/Phase III 
Canertinib (CI10333) EGFR, ErbB2, ErbB3, ErbB4 NSCLC, breast Phase I/II 
EKB-569 EGFR, ErbB2 NSCLC, colorectal Phase II 
BIBW2992 EGFR, ErbB2 NSCLC, breast Phase II 
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PHARMACOKINETICS 
 The pharmacokinetics of a drug is determined by its 
absorption, distribution, metabolism and excretion. The 
bioavailability of a drug is dependent on these four 
properties which are associated with the molecular weight, 
hydrophobicity, hydrophilicity, hydrogen bonding and active 
transport of the drug. Gefitinib and erlotinib have wide 
pharmacokinetic variability in cancer patients [14]. 
Furthermore, it has been shown that the pharmacokinetic 
parameters of gefitinib and erlotinib are different. 
Administration of erlotinib at approved daily dose (150mg) 
achieved approximately 3.5 fold higher steady-state plasma 
concentration than gefitinib with the recommended dose 
(250mg) [15]. Food intake and administration of the drugs 
with food might also increase erlotinib bioavaliability [5]. 
Therefore, gefitinib has lower bioavailability and higher 
systemic clearance than erlotinib [14]. In vitro studies also 
showed that erlotinib is less susceptible than gefitinib to 
metabolism by major liver enzymes and higher plasma 
erlotinib exposure is achieved despite administration of a 
lower erlotinib daily dose when compared with gefitinib 
[14]. Finally, the approved erlotinib dose is administered at 
its maximum tolerated dose while gefitinib dose is one third 
of its maximum tolerated dose [16]. These data might 
explain why the use of erlotinib could result in a clinical 
advantage over gefitinib as its systemic exposure is higher 
than gefitinib. 
 It has been found that smoking also has an effect on 
gefitinib and erlotinib pharmacokinetics. In particular, 
smoking resulted in a higher erlotinib clearance [17]. The 
effect of smoking status on gefitinib is not clear yet although 
it has been reported to be more effective in patients with 
NSCLC who had no smoking history than for the smokers. 
However, the better survival in such subpopulation might be 
due to their favorable natural history rather than the gefitinib 
treatment effects [18]. Indeed, no smoking status can be 
accepted as an important favorable clinical response to both 
gefitinib and erlotinib. 
 Gefitinib and erlotinib may also have different drug-drug 
interaction properties. It has been shown that administration 
of a single dose of rifampicin (a potent CYP3A4 – 
isoenzyme involved in the metabolism of gefitinib - inducer) 
significantly reduces gefitinib systemic exposure by 83%, 
while administration of itraconazole (a potent CYP3A4 
inhibitor) significantly increases it by 78% [19]. It has been 
found that romidepsin increased the sensitivity of erlotinib 
synergistically in NSCLC cell lines including EGFR wild 
type cell lines and TKI resistant EGFR mutant cell lines due 
to the enhanced apoptosis. These observations support a role 
for the combination of a histone deacetylase inhibitor and 
erlotinib in the treatment of NSCLC [20]. 
 However, overall response rates to these drugs remain 
modest and it is difficult to evaluate their pharmacokinetics 
in order to determine the better therapy for each patient [21]. 
First of all, pharmacokinetics of a drug may be different in 
every patient due to the genetic differences in metabolisms. 
Second, the pharmacokinetics of a drug can change over 
time in the same patient. Third, environmental factors, such 
as diet, smoking and body condition can also affect drug 
metabolism. Finally there are several similarities in physical 
and chemical properties in tyrosine kinase inhibitors. 
Therefore, further comparative pharmacokinetic/ 
pharmacogenetic studies should be done in order to 
determine the most effective and safe tyrosine kinase 
inhibitor and to find out the mechanisms that have an 
important role in the development of the variability in drug 
absorption, distribution, metabolism, and excretion, as well 
as drug interaction and clinical effects for the EGFR-TKIs. 
RESISTANCE 
 A major hurdle in cancer treatment is that tumor cells 
have or acquire drug resistance. This happens also for the 
use of TKIs. The resistance to EGFR-TKIs in NSCLC can be 
caused by different mechanisms such as the occurrence of 
resistant mutations in tyrosine kinase receptors, such as the 
EGFR T790M, or the activation of other signalling 
pathways, such as MET overexpression, or the altered 
metabolism or activity of the influx/efflux proteins, resulting 
in lower concentrations of the drugs. 
Genetic Alterations Affecting EGFR-TKIs Activity 
 Higher response rates to EGFR-TKIs have been 
associated with the female gender, adenocarcinoma 
histology, Asian ethnicity, non-smoker status [21]. 
 Specific activating mutations within the EGFR-TK 
domain are associated with these clinical characteristics and 
are predictive of EGFR-TKIs activity [22]. Prospective 
studies with gefitinib or erlotinib in patients harboring EGFR 
activating mutations reported response rates ranging from 60 
to 82%, suggesting that these drugs might be a valuable 
alternative to chemotherapy in selected NSCLC patients 
[23]. In contrast, recent studies also identified mutations in 
EGFR associated with resistance. 
 In response to ligand binding EGFR is activated via 
dimerization and the phosphorylation of the tyrosine kinase 
domain which results in the activation of different 
downstream signalling pathways such as MAPK, STAT, 
SRC/FAK and PI3K/AKT which forms an intersecting 
network and stimulates cell growth and proliferation [24]. 
When EGFR is mutated, cell growth is triggered without 
restrictions. Deregulation of protein synthesis, cell cycle, cell 
growth, cell division, apoptosis and angiogenesis results in 
carcinogenesis. EGFR alterations and mutations, involving 
either the receptor itself or the downstream effectors, are 
frequent in NSCLC [25]. The identification of these 
mutations and alterations which result in different sensitivity 
to tyrosine kinase inhibitors in EGFR-directed therapies is 
crucial for the selection of the right tyrosine inhibitors and 
decrease resistance. 
EGFR Mutations in NSCLC 
 Initial in vitro studies showed that mutated EGFR 
significantly increased and prolonged activation when 
compared to wild type [26], favouring EGFR-TKIs activity, 
but there are different subtypes of EGFR mutations. 
 Mutation frequency in NSCLC is recognized to vary 
across ethnic groups, with a notably higher prevalence 
observed in East-Asian trials (30% to 60%), than in North 
American studies (10% to 20%) (Fig. 2). Approximately 
90% of the EGFR mutations affect regions within exon 18 to 
21, which code for tyrosine kinase domain [27]. In-frame 
deletion in exon 19 accounts for approximately 50% of the 
30    The Open Lung Cancer Journal, 2010, Volume 3 Olcay et al. 
cases and it eliminates four amino acids (LREA) that lie 
downstream of lysine residue at position 745 [28]. The 
missense mutation at codon 858 that leads to the substitution 
of leucine by an arginine (L858R) accounts at least 35% of 
EGFR mutations in NSCLC. The remaining 5% mutations 
are the insertions in exon 20. Finally, there are also rare 
substitutions which span exon 18 to 21 [25]. The mutations 
in EGFR affect sensitivity to EGFR inhibitors. In lung 
cancer, activating EFGR tyrosine kinase domain mutations 
are associated with increased clinical efficacy of erlotinib 
and gefitinib [26]. 
 The mechanisms of how EGFR mutations are involved in 
NSCLC development and the tumors become sensitive to 
treatment are not fully understood. Previous studies showed 
that the EGFR exon 19 deletion and L858R mutation triggers 
the ligand-independent activation and extends the receptor 
kinase activity after it is stimulated by the ligand binding 
[22, 29]. In vitro studies suggested that the mutations in 
EGFR kinase domain are sufficient for oncogenic 
transformation as exon 19 deletion, exon 20 insertion and 
exon 21 L858R can transform fibroblasts [28]. 
 However, patients with EGFR mutations can hardly 
achieve a complete response. The continued treatment of the 
tumor by gefitinib or erlotinib cures the drug-sensitive cells 
whereas a population of tumor cells which gain resistance to 
gefitinib or erlotinib are also developed. To understand the 
mechanisms of aquired resistance, tumors from NSCLC 
patients who showed initial sensitivity to gefitinib or 
erlotinib and then developed an acquired resistance were 
analyzed. These studies showed that additional EGFR 
mutations are also found in the tumors with acquired 
resistance [30]. In patients with tumors bearing gefitinib- or 
erlotinib-sensitive EGFR mutations, resistant subclones 
containing an additional EGFR mutation emerge in the 
presence of drug [31]. Therefore, lung adenocarcinomas 
from patients who respond to the tyrosine kinase inhibitors 
gefitinib or erlotinib usually harbor somatic gain-of-function 
mutations in exons encoding the kinase domain of the EGFR 
[31]. Despite the initial responses, patients eventually 
progress by mechanisms of acquired resistance. 
 Acquired resistance can develop by several mechanisms. 
About 50% of the resistance to gefitinib and erlotinib are 
caused by secondary mutations such as the exon 20 point 
mutation (T790M) or the insertion in exon 20 
(D770_N771insNPG) in the EFGR gene [32]. The insertion 
involving exon 20 has been related with a poor tumor 
response and can also be related to primary resistance [33]. 
The tyrosine kinase domain mutation which is a point 
mutation in exon 19 (D761Y) is also associated with drug 
resistance [34]. However the most important mutation 
associated with drug resistance and tumor relapse [35] is the 
exon 20 point mutation (T790M), which changes threonine 
into methionine at position 790 in the catalytic cleft of the 
EGFR tyrosine kinase domain [24] and is associated with 
resistance. This resistance might be due to the blocking of 
the binding of erlotinib or gefitinib to the kinase ATP-
binding pocket [34]. Other in vivo studies suggested that the 
acquired resistance might be due to the alterations in receptor 
turnover [36]. 
 Therefore, characterization of the genetic alterations of 
the relapsed tumor could help to decrease the resistance and 
optimize the therapy. 
 Mutations outside the exons encoding the kinase domain 
are rare in lung cancers [22], however the EGFRvIII 
mutations have also been found in some NSCLC, especially 
in squamous cell carcinomas [37]. In particular a recent 
study genotyped the EGFRvIII mutation status in 252 
surgically treated lung cancer cases, and this mutation was 
detected in 8 of 252 patients [38]. All patients were male, 
smokers, and 7 had squamous cell carcinoma. Of note, 
EGFR gene copy number was significantly higher in 
EGFRvIII mutants, suggesting that EGFRvIII gene mutation 
might be one of the mechanisms of increased EGFR copy 
number. However, further studies are needed to confirm the 
mechanisms of EGFRvIII mutations for possible anti-EGFR 
therapy for lung cancer. 
 EGFR activating mutations are also associated with 
amplification, and increased EGFR copy number has also 
been reported to be associated with response and survival to 
EGFR tyrosine kinase inhibitors [24]. It has been shown in a 
previous study that the patients with amplification of EGFR 
had significantly improved response of gefitinib when 
compared with the patients who have normal, low or no 
EGFR copy number [39]. Furthermore, MET amplification 
has also been identified as a mechanism of acquired 
resistance to gefitinib and erlotinib through secondary 
mutations in different studies [40, 41]. 
 
Fig. (2). Mutations associated with sensitivity to gefitinib or erlotinib in EGFR gene in NSCLC (top). Mutations associated with resistance to 
gefitinib or erlotinib (bottom). 
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 Finally, Sos et al. showed that in EGFR-dependent cells, 
PTEN loss partially uncouples mutant EGFR from 
downstream signaling and activates EGFR, thereby 
contributing to erlotinib resistance [42]. The clinical 
relevance of these findings is supported by the observation 
of PTEN loss in 1 out of 24 primary EGFR-mutant non-
small cell lung cancer (NSCLC) tumors. These results 
suggested a novel resistance mechanism in EGFR-mutant 
NSCLC involving PTEN loss [42]. These findings and 
observations should help to guide the search for more 
effective therapy with tyrosine kinase inhibitors against a 
specific subset of lung cancers. 
MET Overexpression in NSCLC with EGFR Mutations 
 In many cancer types, drug resistance is caused by the 
overexpression and amplification of the target kinase and in 
NSCLC, an important mechanism involved in resistance to 
gefitinib and erlotinib is the amplification of MET. The 
amplification of MET is observed in approximately 20% of 
the NSCLC tumors resulting in the activation of PI3K/Akt 
signalling by ErbB3 phosphorylation without the 
involvement of EGFR and ErbB2 [39]. It has been found that 
MET physically interacts with both EGFR and Her2 in a 
NSCLC cell line with overexpression and overactivation of 
MET. Therefore, combined use of a dual EGFR/Her2 
inhibitor with a MET inhibitor yields maximal growth 
inhibition [43]. 
 Many NSCLC cell lines express total MET protein and a 
subset of MET-expressing NSCLC cell lines also expressed 
the phosphorylated forms. In particular, phospho-MET 
expression was significantly related to increased MET copy 
number and was significantly more frequent in EGFR mutant 
cell lines [44]. As an additional evidence for the relation 
between EGFR mutation and MET activation, it has been 
suggested that other tyrosine kinases were also activated in 
cells with EGFR activation by EGFR mutations [44]. Guo et 
al. also showed that three EGFR mutant cell lines harboring 
phospho-MET expression without MET amplification lost or 
decreased phospho-MET expression whereas MET amplified 
cell lines with or without EGFR mutations retained phospho- 
MET expression after knockdown of EGFR, indicating that 
EGFR mutation or MET amplification activate MET protein 
[45]. Therefore, MET amplification is present in a subset of 
untreated lung cancers and cell lines with or without EGFR 
mutations, and EGFR mutation or MET amplification lead to 
activation of MET. The combination of MET inhibitors and 
EGFR inhibitors can offer a more effective treatment for 
NSCLC patients with gefitinib and erlotinib resistance. For 
example a second tyrosine kinase inhibitor which is against 
MET should be administered with gefitinib or erlotinib. 
EGFR Polymorphisms 
 Several studies have investigated the polymorphisms in 
EGFR and EGFR related pathways and their relation with 
EGFR TKIs in NSCLC. Many of those studies are focused 
on the intron 1 CA repeat polymorphism. The CA simple 
sequence repeat 1 (CA-SSR1) is a highly polymorphic locus 
in intron 1 of EGFR and it contains 14-21 CA dinucleotide 
repeats [46, 47]. Length of CA repeat is inversely correlated 
with EGFR gene transcription therefore shorter alleles have 
higher transcription [48]. In tumors, short CA repeats are 
associated with higher EGFR expression when compared 
with long CA repeats. Another functional EGFR 
polymorphism is the -216G/T polymorphism which is 
located at the promoter region of EGFR and changes guanine 
to thymine. It is located in an important binding site for 
transcription factors and the T allele is associated with a 
higher EGFR expression [24]. 
 Most of the studies suggest that shorter CA repeat length 
is associated with better response and survival in patients 
with EGFR TKIs [47, 49]. It has been shown that the 
classical EGFR mutations predicted sensitivity to gefitinib 
and there was a trend toward shorter CA repeats being 
associated with longer survival among the patients with 
drug-sensitive EGFR mutation [50]. Nie et al., also showed 
the association of improved survival with shorter CA repeats 
in Chinese patients who were treated with gefitinib for the 
CA repeat polymorphism [51]. Similarly, it has been found 
that classical EGFR mutations are associated with response 
and survival in patients treated with gefitinib for EGFR 
mutation and CA repeat polymorphism with a trend towards 
higher response rates among patients with low CA repeats 
[52]. However, Gregorc et al., evaluated patients treated with 
gefitinib for EGFR intron 1 and -216G/T polymorphisms. 
They showed that the outcome of treatment with gefitinib in 
patients with NSCLC is dependent on the genetic variability 
in the promoter region of EGFR gene. They did not find any 
relation with the intron 1 CA repeat polymorphism while the 
ones with 216G/T polymorphism showed lower response 
rates [53]. Furthermore, Nomura et al., showed that the two 
EGFR promoter polymorphisms are unrelated to survival in 
NSCLC patients who were not treated with EGFR TKIs after 
adjusting for sex, ethnicity, age and smoking. These authors 
suggest that EGFR intron 1 does not affect the growth of 
NSCLC independent of the treatment with gefitinib [54]. 
 In conclusion, several common germline polymorphisms 
in the promoter region of the EGFR gene can be associated 
with clinical benefit, progression time and survival of 
NSCLC patients with gefitinib treatment and further studies 
in this setting are waranted. 
CONCLUSION 
 Targeted therapy focuses on the differences in the genetic 
background between the tumor cells and the normal cells and 
it aims to attack specifically the tumor cells. Currently, 
EGFR inhibition is an important strategy used for the 
treatment of NSCLC. EGFR inhibitors, such as the tyrosine 
kinase inhibitors erlotinib and gefitinib are one of the most 
commonly used treatment strategies. Alterations in EGFR 
have a major importance in EGFR tyrosine kinase inhibition 
response, whereas modifications that occur on the 
downstream effectors could also lead to resistance. 
Secondary mutations result in resistance by interfering with 
the binding of tyrosine kinase inhibitors, thus resulting in a 
decreased sensitivity. The altered pathways are also different 
in individuals because of the genetic diversity in metabolism. 
 Therefore, a better and more detailed characterization of 
the mechanisms of resistance causing events would help to 
decrease the resistance and optimize the therapy. In the 
future, finding better predictors of response, resistance and 
survival could be critical to determine the patients who 
might get the best benefit from specific treatments. 
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